JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Kura Oncology Inc

Aperta

SettoreSettore sanitario

10.55 -2.5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.33

Massimo

10.85

Metriche Chiave

By Trading Economics

Entrata

-8.7M

-66M

Vendite

1.2M

15M

Margine di Profitto

-432.509

Dipendenti

192

EBITDA

-8M

-73M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+147.38% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

320M

867M

Apertura precedente

13.05

Chiusura precedente

10.55

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Kura Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 ott 2025, 23:50 UTC

Azioni calde

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 ott 2025, 23:25 UTC

Utili

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 ott 2025, 23:18 UTC

Utili

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 ott 2025, 22:20 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 ott 2025, 22:13 UTC

Utili

Wal-Mart de Mexico Net Profit Falls in 3Q

28 ott 2025, 21:38 UTC

Utili

Correction to Visa Sales Jump Article

28 ott 2025, 21:17 UTC

Utili

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 ott 2025, 21:07 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- Update

28 ott 2025, 21:02 UTC

Utili

Mondelez Tempers Outlook as Costs Rise

28 ott 2025, 23:51 UTC

Discorsi di Mercato

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 ott 2025, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 ott 2025, 23:02 UTC

Utili

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 ott 2025, 23:01 UTC

Utili

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 ott 2025, 22:46 UTC

Utili

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 ott 2025, 22:45 UTC

Utili

SK Hynix 3Q Net KRW12.6T >000660.SE

28 ott 2025, 22:44 UTC

Utili

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 ott 2025, 22:43 UTC

Utili

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 ott 2025, 22:42 UTC

Utili

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 ott 2025, 22:20 UTC

Utili

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 ott 2025, 22:02 UTC

Utili

Review & Preview: Earnings Extravaganza -- Barrons.com

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 ott 2025, 21:20 UTC

Utili

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 ott 2025, 21:19 UTC

Utili

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 ott 2025, 21:18 UTC

Utili

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Confronto tra pari

Modifica del prezzo

Kura Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

147.38% in crescita

Previsioni per 12 mesi

Media 26 USD  147.38%

Alto 40 USD

Basso 11 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Kura Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

11

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.575 / 6.6Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

154 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat